Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.
Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.
复制标题
DOI：
10.3390/medsci10010015
复制
发表时间：
2022-02-18
期刊：
影响因子：
--
通讯作者：
Omarzai Y
中科院分区：
文献类型：
--
作者：
Bahmad HF;Demus T;Moubarak MM;Daher D;Alvarez Moreno JC;Polit F;Lopez O;Merhe A;Abou-Kheir W;Nieder AM;Poppiti R;Omarzai Y
前列腺癌（PCa）是男性中第二常见的癌症。常见的治疗方法包括主动监测、手术或放射治疗。雄激素剥夺疗法和化疗通常用于晚期疾病或生化复发，如去势抵抗性前列腺癌（CRPC），但它们不被认为是治愈性的，因为PCa细胞最终会产生耐药性。后者是通过最终绕过药物作用模式的各种细胞机制实现的。在这种情况下，需要新的治疗方法是必要的。治疗PCa的另一种方法是重新利用最初用于其他疾病的现有药物。通过将先前批准的药物的作用外推到PCa的细胞内过程，治疗选择将扩大。此外，药物再利用具有成本效益和效率，因为它使用已经证明安全性和有效性的药物。本综述对临床前研究和临床试验中可用于PCa的药物进行了分类。
Prostate cancer (PCa) is the second most common cancer in men. Common treatments include active surveillance, surgery, or radiation. Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as castration-resistant prostate cancer (CRPC), but they are not considered curative because PCa cells eventually develop drug resistance. The latter is achieved through various cellular mechanisms that ultimately circumvent the pharmaceutical’s mode of action. The need for novel therapeutic approaches is necessary under these circumstances. An alternative way to treat PCa is by repurposing of existing drugs that were initially intended for other conditions. By extrapolating the effects of previously approved drugs to the intracellular processes of PCa, treatment options will expand. In addition, drug repurposing is cost-effective and efficient because it utilizes drugs that have already demonstrated safety and efficacy. This review catalogues the drugs that can be repurposed for PCa in preclinical studies as well as clinical trials.
影响因子：
6.2
作者：
Marcella SW;David A;Ohman-Strickland PA;Carson J;Rhoads GG
通讯作者：
Rhoads GG